Navigation Links
SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
Date:11/6/2009

eserve our capital and improve our position for the future."

Total revenues, which consist of royalty revenue from our collaboration agreements, increased 11%, or $25,343 to $261,651 for the three months ended September 30, 2009, compared to $236,308 for the same period in 2008. Total revenues decreased 15%, or $117,223 to $664,212 for the nine months ended September 30, 2009, compared to $781,435 for the same period in 2008. Royalty revenues result from our relationship with Perrigo and reflect changes in the level of sales by Perrigo.

Marketing and selling expenses decreased 53%, or $62,489 to $54,351 for the three months ended September 30, 2009, compared to $116,840 for the same period in 2008 and decreased 63%, or $345,177 to $200,402 for the nine months ended September 30, 2009, compared to $545,579 for the same period in 2008. These decreases are due to a reduction in personnel related expenses due to reduction in personnel and lower advertising and tradeshow expenses.

Research and development expenses decreased 75%, or $1.7 million to $572,189 for the three months ended September 30, 2009, compared to $2.3 million for the same period in 2008 and decreased 50%, or $2.2 million to $2.2 million for the nine months ended September 30, 2009, compared to $4.4 million for the same period in 2008. These decreases were primarily due to our decision to defer development activities on certain projects pending additional funding and a reduction in personnel related expenses due to personnel reductions.

General and administrative expenses increased 29%, or $273,061 to $1.2 million for the three months ended September 30, 2009, compared to $947,684 for the same period in 2008, and increased 3%, or $104,665, to $3.3 million for the nine months ended September 30, 2009, compared to $3.2 million for the same period in 2008. These increases were primarily due to severance costs associated with the resignation of our former CEO,
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
2. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
3. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
4. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
5. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
6. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
7. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
8. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
9. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
10. Northern Light Adds 4,000 Bio-Pharma, Health Sciences and General Business News and Journal Sources from EBSCO Publishing
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... MINNEAPOLIS, Nov. 20 Bi...ults for its first quarter ended September 30, 200...ted share, on revenues of $3,263,000. This compar...ed share, on revenues of $3,168,000 for the first ...t quarter results, Biotel President and CEO Steve ...
(Date:11/20/2009)..., PRINCETON, N.J., Nov. 20 /PRNewswire-FirstCall...oligenix or the Company), formerly known as DOR Bi... announced today that it has formed a consortium t...(TM) and other rapidly acting vaccines. Soligenix ...stitute of Allergy and Infectious Diseases (NIAID)...
(Date:11/19/2009)..., TAINAN, Taiwan, Nov. 19 /PRNewswire-Asia/ ... pharmaceutical ingredients (APIs), announced that...und Safety Certification from,SafeBridge(R) Consul...s,competency and proficiency in the safe handling ..., and applies to specific laboratories and,product...
Breaking Medicine Technology:Biotel Announced Profitable First Quarter Ended September 30, 2009 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 1Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 2Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 3Gluten Free Superstore Opens With 4 000 Products 59885 1Gluten Free Superstore Opens With 4 000 Products 59885 2Medical Liability Monitor Annual Survey of Medical Malpractice Insurance Rates Shows Medical Liability Insurance Market Remains Soft 59883 1Medical Liability Monitor Annual Survey of Medical Malpractice Insurance Rates Shows Medical Liability Insurance Market Remains Soft 59883 2
...s Internal Pipeline as DARA Program Enters P...s Added, PRINCETON, N.J., Nov. 1 Pharmacopeia (N...er and nine months ended,September 30, 2007, and h...herapeutic programs and corporate milestones achie...e third quarter of 2007: -- Pharmacopeia announce...
...ories, Inc.,(NYSE: FRX ) today announced the resu...ed clinical trial, published in the November 2007 ...ch demonstrated that nebivolol,significantly reduc...sed as,monotherapy among African-American patients...d that nebivolol was well tolerated in comparison ...
Other Medicine Technology:Pharmacopeia Announces Third Quarter 2007 Financial Results 2Pharmacopeia Announces Third Quarter 2007 Financial Results 3Pharmacopeia Announces Third Quarter 2007 Financial Results 4Pharmacopeia Announces Third Quarter 2007 Financial Results 5Pharmacopeia Announces Third Quarter 2007 Financial Results 6Pharmacopeia Announces Third Quarter 2007 Financial Results 7Pharmacopeia Announces Third Quarter 2007 Financial Results 8Pharmacopeia Announces Third Quarter 2007 Financial Results 9Pharmacopeia Announces Third Quarter 2007 Financial Results 10Pharmacopeia Announces Third Quarter 2007 Financial Results 11UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension 2UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension 3
(Date:11/20/2009)..., NEW YORK, Nov. 20 S...that it will broadcast Doctor Radio Reports: Wh... in-depth special hosted by veteran journalist Per...i-bin/prnh/20080819/NYTU044LOGO ) ,, Doctor R...t Mammograms will air November 21 live at 10:00...
(Date:11/20/2009)...tions of exposure to formaldehyde used for embalmi... increased risk of death from myeloid leukemia, ac...0 in the Journal of the National Cancer Institute...y from lymphohematopoietic malignancies and brain ...dustry workers, all of whom may have worked with f...
(Date:11/20/2009)... Washington) November 20, 2009Emergency medical se...an estimated 350,000 cardiac arrests each year. O...iac arrest survive. Better quality cardiopulmonar...providers may be associated with better patient ou...) is the largest clinical research network to stud...
(Date:11/20/2009)...ks it,s as short as 34 weeks, potentially adding t... FRIDAY, Nov. 20 (HealthDay News) -- Recent report...es to climb in the United States. Now, a new stud... about what constitutes a full-term birth in the f...surveyed in the study considered a baby born at 34...
(Date:11/20/2009)...udy finds more severe cases than with seasonal flu...- Canadian researchers are reporting that children...es of H1N1 flu than seasonal flu. , "Asthma has...admission with pandemic H1N1 influenza, present in...wrote Dr. Upton Allen and fellow researchers from ...
Breaking Medicine News(10 mins):Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 3Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 4Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 5Health News:Funeral industry workers exposed to formaldehyde face higher risk of leukemia 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3Health News:Many Women Miscalculate Time to Full-Term Birth 2Health News:Many Women Miscalculate Time to Full-Term Birth 3Health News:Many Women Miscalculate Time to Full-Term Birth 4
...e latest developments in drug discovery including...rthwick Park drug-trial disaster and issues surrou...e highlighted at a conference in Brighton next wee...t, attracting experts from across the world. , Ru...
...OOK, N.J., Dec. 12 Seabrook House is proud to ann... educational seminar "How to Change Someone You Lo..., author of "How to Change Someone You Love" and n...h -- beginning Tuesday, January 13th, 2009 at 6:30...
... American Board of Medical Sp...certification of physician specialists in the Unit...ACP, senior vice president for professional and sc...its various committees to help promote the science...
...PORE and CHICAGO, Dec. 12 Aon Corporation,(NYSE: ...sk management and,consulting services, today annou...s regional director of Aon Environmental Services .../www.newscom.com/cgi-bin/prnh/20041215/CGW049LOGO ...
...LIFF LAKE, N.J., Dec. 12 Par Pharmaceutical Compa...gnation of Veronica A. Lubatkin, executive vice pr...ch 6, 2009, to pursue other professional opportuni...cial officer on March 9, 2009. Mr. Kenyon joins f...
...merican physicians often overlook the illness, del...hDay News) -- Many doctors view leprosy as a scou... are still thousands of U.S. cases, with more diag...ssing its diagnosis, say experts who discussed the...
Other Medicine News:Health News:Leading pharmacologists to meet in Brighton 2Health News:'How to Change Someone You Love' Seminar Offers Help to Those Who Feel Powerless in the Face of Addiction 2Health News:'How to Change Someone You Love' Seminar Offers Help to Those Who Feel Powerless in the Face of Addiction 3Health News: ABMS Appoints Richard Hawkins, MD, FACP as New Senior Vice President for Professional and Scientific Affairs 2Health News: ABMS Appoints Richard Hawkins, MD, FACP as New Senior Vice President for Professional and Scientific Affairs 3Health News:Aon Appoints Environmental Veteran to Oversee Risk Management Services for Clients in Far East, Asia and Australia 2Health News:Aon Appoints Environmental Veteran to Oversee Risk Management Services for Clients in Far East, Asia and Australia 3Health News:Par Pharmaceutical Announces the Resignation of Its Chief Financial Officer 2Health News:Leprosy Lingers in the U.S. 2Health News:Leprosy Lingers in the U.S. 3
LM 15A
LM-101 Standard Lensmeter
LM-S1 Lensmeter
Eye Q Lite
Medicine Products: